Pfizer presents SA3Ag staphylococcal vaccine Phase 1 trial data at ECCMID/ICC

Inhibitex, Inc. (Nasdaq: INHX), announced today that Pfizer Inc. presented safety and immunogenicity data from a Phase 1 double-blind randomized placebo controlled study in 408 healthy volunteers of a novel three antigen Staphylococcus aureus investigational vaccine (SA3Ag) at the 21^st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and 27^th International Congress of Chemotherapy (ICC) in Milan, Italy (ECCMID/ICC). The vaccine candidate is comprised of S. aureus capsular polysaccharide serotypes 5 and 8 conjugated to CRM₁₉₇ and the recombinant surface-expressed MSCRAMM protein, clumping factor A. In the Phase 1 study, the vaccine elicited a positive immune response to each of the three components. Pfizer has worldwide exclusive rights to the Company's MSCRAMM protein platform for the development of staphylococcal vaccines.

"We are very encouraged with the initial safety and immunogenicity profile of SA3Ag in this Phase 1 trial," stated Dr. Joseph Patti, Senior Vice President and Chief Scientific Officer of Inhibitex, Inc. "We are pleased with the clinical progress of the staph vaccine program by our partner Pfizer and look forward to its continued development."